Pure Global
NCT05283317

Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock

The Effect of Mesenchymal Stromal Cells on the Mortality of Patients With Sepsis and Septic Shock: A Promising Therapy
TC Erciyes University·Phase 1/2·ClinicalTrials.gov·biologicalCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
Mesenchymal stem cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
TC Erciyes University
Location
Kayseri, Turkey
Timeline & enrollment
Phase
Phase 1/2
Start date
Mar 11, 2018
End date
Nov 13, 2019
Enrollment
30 participants
Primary outcome

Mortality

Summary

Methods:Ten patients were enrolled in the study. Adipose derived-MSCs infusions were given
 (1x 106/ kg, on 1st, 3rd, 5th, 7th and 9th days of therapy) together with Standard therapy.
 Before the MSCs applications, blood samples were collected for cytokine assessment (TNF-α,
 IFN-γ, IL-2, IL-4, IL-6, IL-10). The clinical and laboratory improvements were recorded and
 compared with control groups selected retrospectively.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05283317
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05283317 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by TC Erciyes University and is currently Completed. The study focuses on Sepsis,Septic Shock. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.